Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD3xTRP-1 bispecific antibody
- Development stage
- Preclinical
- Lead developer
- Absolute Antibody
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intraperitoneal, Intravenous
01
Overview
CD3xTRP-1 bispecific antibody (also known as bAb0136) is a recombinant, bispecific, knob-into-hole (KIH) heterodimerized antibody designed for preclinical research in cancer immunotherapy. It features one arm with an anti-mouse CD3e single-chain variable fragment (scFv) derived from clone 145-2C11 and another arm containing the TA99 clone directed against tyrosinase-related protein-1 (TRP-1/gp75). Built on a murine IgG2a backbone with an Fc Silent™ mutation to eliminate antibody-dependent cellular cytotoxicity (ADCC), this bispecific antibody cross-links T cells with TRP-1-expressing tumor cells, such as melanoma, to induce local T-cell activation and tumor cell lysis. It is widely used in syngeneic mouse models to study the pharmacokinetics, biodistribution, and therapeutic efficacy of CD3-targeting bispecific antibodies.
- Other names
- CD3xTRP-1CD-3xTRP-1CD 3xTRP-1CD3xTRP1CD-3xTRP1CD 3xTRP1CD3xTRP1 bispecific antibodyCD-3xTRP1 bispecific antibodyCD 3xTRP1 bispecific antibodyanti-TRP-1 x anti-CD3 bispecific antibodyanti-TRP1 x anti-CD3 bispecific antibodyanti-TRP 1 x anti-CD3 bispecific antibody
02
Targets
CD3 (T-cell surface glycoprotein CD3)TYRP1 (Tyrosinase-related protein 1)
Beyond the preview
Go deeper on CD3xTRP-1 bispecific antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD3xTRP-1 bispecific antibody.